The blood industry has been shaken by a series of seismic shifts in recent years and the next shock is already cresting the horizon: Pathogen Reduction Technology (PRT) has the potential to transform how blood products reach patients. Other upsets have been sudden and jarring, such as 2016’s Zika epidemic and its nation-wide impact on blood availability.  In the span of a single year, an emerging pathogen was identified as a threat to the blood supply, nucleic acid tests were developed, and a new guidance was adopted by the FDA.